Oral Transmucosal Testosterone Formulation with Aromatase Inhibitor
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for testosterone deficiency, such as transdermal and injectable therapies, suffer from high dosages, side effects like local pain and skin irritation, and inefficiencies in testosterone absorption, while oral transmucosal delivery methods lack effective aromatase inhibitors for maintaining physiologic estradiol levels.
Innovation Solution
Development of oral transmucosal compositions combining low doses of testosterone with aromatase inhibitors like anastrozole, utilizing transmucosal absorption enhancers to increase bioavailability and avoid hepatic metabolism, allowing for direct absorption into the bloodstream, thereby maintaining physiologic testosterone and estradiol levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If transdermal testosterone therapy is used, then testosterone levels are maintained, but skin irritation and local pain occur due to high ethanol content
Solution Approach 1:
The patent changes the physical state of testosterone from solid to liquid by using a testosterone suspension in alcohol-free vehicle, eliminating the need for ethanol as a solvent and thereby removing the cause of skin irritation while maintaining testosterone delivery effectiveness
Solution Approach 2:
The patent extracts and removes ethanol from the formulation entirely, replacing it with an alcohol-free vehicle that suspends testosterone particles, thereby eliminating the harmful effect of ethanol-induced skin irritation while preserving the therapeutic function
2Reliability
If high doses of testosterone are administered, then serum testosterone levels reach normal range, but side effects increase
Solution Approach 1:
The patent uses a sustained release mechanism that provides partial dosing over extended periods, releasing testosterone gradually to maintain serum levels within normal range without requiring high single doses, thereby reducing peak-related side effects
Solution Approach 2:
The patent employs a sustained release formulation that periodically releases testosterone over time, creating a controlled periodic delivery pattern that maintains stable serum levels and avoids the fluctuations and side effects associated with high intermittent dosing
3Productivity
If oral transmucosal delivery is used, then first-pass effect is avoided and onset time is reduced, but effective aromatase inhibitors are lacking
Solution Approach 1:
The patent combines testosterone with an aromatase inhibitor (anastrozole) in a single oral transmucosal formulation, merging two therapeutic agents into one product that can be administered together through the same delivery route, thereby providing both testosterone replacement and estrogen control without requiring separate administrations
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The synergistic combination of low-dose testosterone and aromatase inhibitors in oral transmucosal compositions effectively increases testosterone levels without high estrogen side effects, providing a more efficient and patient-friendly treatment for testosterone deficiency.
Implementation Method 1
Oral transmucosal administration involves the patient holding the composition in the oral cavity while the API dissolves in the available fluid, diffuses through the mucosa lining of the mouth, and enters the bloodstream bypassing the gastrointestinal tract as well as hepatic metabolism
Implementation Method 2
AIs work by binding to the aromatase and inhibiting this enzyme that converts testosterone into estrogen
Implementation Method 3
the API dissolves in the available fluid, diffuses through the mucosa lining of the mouth, and enters the bloodstream
Data Source
AI summary
Formulations for oral transmucosal compositions including a synergistic combination of low doses of testosterone with an aromatase inhibitor (AI) that are combined with transmucosal absorption enhancers are disclosed. Oral transmucosal compositions can be for fast release or slow release, and can be administered to increase bloodstream testosterone levels and thereby reduce symptoms of testosterone deficiency. Oral transmucosal compositions include liquid dosage forms, solid dosage forms, and chewing gums. Further dosage forms include mucoadhesive thin strips, thin films, tablets, patches, and tapes, among others. Other dosage forms are: mucoadhesive liquids such as gel-forming liquids; gel-forming semisolids; and gel-forming powders, among other dosage forms that exhibit mucoadhesive properties, and provide oral transmucosal delivery of testosterone and AI. Oral transmucosal compositions will deliver testosterone and AI directly into the patient's bloodstream, and provide high bioavailability of testosterone and AI; therefore, the required doses are lower.